The initial success of the copyright undeniably reshaped the medication landscape, but betting in companies strongly reliant on generic versions presents a complex picture. Although early returns were substantial, the cessation of patents and the rise of less expensive alternatives have eroded market share. Therefore, a thorough assessment of ongoi